We are live on ! Find out more
ARCT icon

Arcturus Therapeutics
ARCT

23 hedge funds and large institutions have $17.7M invested in Arcturus Therapeutics in 2019 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

159% more call options, than puts

Call options by funds: $381K | Put options by funds: $147K

100% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 4

78% more capital invested

Capital invested by funds: $9.98M → $17.7M (+$7.75M)

21% more funds holding

Funds holding: 19 → 23 (+4)

0.73% more ownership

Funds ownership: 13.58% → 14.31% (+0.73%)

0% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 5

Holders
23
Holders Change
+4
Holders Change %
+21.05%
% of All Funds
0.5%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
5
Reduced
5
Closed
4
Calls
$381K
Puts
$147K
Net Calls
+$234K
Net Calls Change
+$152K

Top Buyers

1
HCM
Highline Capital Management
New York
+$1.25M
2
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group
Japan
+$954K
3
AIM
ARK Investment Management
Florida
+$567K
4
NAMA
Nikko Asset Management Americas
New York
+$483K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$302K

Top Sellers

1
DCM
DAFNA Capital Management
California
-$329K
2
Morgan Stanley
Morgan Stanley
New York
-$197K
3
DC
Diametric Capital
Massachusetts
-$125K
4
PCM
Prelude Capital Management
New York
-$53.4K
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$38K
Name Holding Trade Value Shares
Change 		Change in
Stake
Barclays
26
Barclays
United Kingdom
– -$1K -84 Closed
TRCT
27
Tower Research Capital (TRC)
New York
– +$382 +52 New
1
2

ARCT Hedge Fund Activity: Q2 2019 in Review

23 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Arcturus Therapeutics (ARCT) for Q2 2019, worth a combined $17.7M — up 78% from $9.98M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new ARCT positions and 4 closed out — a net gain of 4 holders — while 5 added to existing stakes and 5 trimmed.

The largest buyer was Highline Capital Management, adding an estimated $1.25M. The largest seller was DAFNA Capital Management, cutting an estimated $329K.

  • 23 institutional investors held Arcturus Therapeutics (ARCT) as of Q2 2019, up from 19 in Q1 2019.
  • Funds reported $17.7M of Arcturus Therapeutics stock for Q2 2019, up 78% quarter-over-quarter.
  • 8 funds opened new Arcturus Therapeutics positions in Q2 2019 and 4 closed out, a net change of +4 holders.
  • The largest Arcturus Therapeutics buyer in Q2 2019 was Highline Capital Management, an estimated $1.25M added.
  • The largest Arcturus Therapeutics seller in Q2 2019 was DAFNA Capital Management, an estimated $329K sold.

Based on aggregated 13F filings for Q2 2019.